Clinical Trial

The Impact of Salmon Protein Hydrolysate (SPH / ProGo®) Supplementation on Hematologic and Metabolic Health

Completed
View on ClinicalTrials.gov →
Summary
Healthy, overweight males and females randomised to receive 8-weeks of salmon protein hydrolysate SPH (12g daily) or whey protein isolate (12g daily) to assess the impact on red blood cell and ferritin levels, blood glucose levels, BMI, percent body fat and lean body mass along with hair, skin and nail health and blood biomarkers of inflammation.
Trial Details
NCT Number NCT07616752
Lead Sponsor Hofseth Biocare ASA
Conditions Overweight (BMI > 25), Weight Loss
Enrollment 14 participants
Start Date 2019-07-19
Primary Completion 2019-11-03 (estimated)
Study Completion 2020-01-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-01